A recent population-based cohort study found no significant increase in the risk of melanoma (HR, 0.96; 95% CI, 0.53–1.75) or non-melanoma skin cancers (HR, 1.03; 95% CI, 0.80–1.33) among GLP-1 RA users compared to sulfonylurea users [25]. This evidence concerns the gene GCG and melanoma.